Abbott Laboratories (ABT) 2025 Earnings Quality Report

Grade: C — Solid Cash Flow, Two Items to Monitor

Framework: Schilit *Financial Shenanigans* + Beneish M-Score + forensic accounting principles

Data: SEC EDGAR 10-K (Filed 2026-02-20, fiscal year ended December 31, 2025) + Yahoo Finance

Auditor: Ernst & Young LLP — Clean opinion (1 Critical Audit Matter)

One-line verdict: Abbott is the Swiss-army-knife of healthcare — four reportable segments (Established Pharmaceuticals, Diagnostic Products, Nutritional Products, Medical Devices) spanning branded generics in emerging markets to the FreeStyle Libre continuous glucose monitor and the MitraClip transcatheter valve. Revenue grew 5.7% to $44.3B in 2025, CFFO of $9.6B covered net income of $6.5B at 1.47x, and free cash flow of $7.4B comfortably funded the $4.1B dividend. The Altman Z-Score of 4.90 is one of the strongest in large cap healthcare. Two items warrant attention: accounts receivable grew 14.5% against revenue growth of 5.7% for the second year in a row (A2 fail), and goodwill plus intangibles of $29.6B equal 57% of stockholders' equity (D1 fail). The 10-K's Critical Audit Matter — $4.0B in unrecognized tax benefits — reminds readers that operating in "numerous countries" creates structural estimation uncertainty. The underlying business is fine; earnings quality is good; two data points deserve footnote reading.

Business: Four Segments, Extreme Diversification

Per Item 1 of the 10-K: "Abbott has four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices."

The filing describes the portfolio:

Per the segment table, Medical Devices is now the largest segment at $21,387M in 2025 (vs $18,986M in 2024, +12.7%), and Diagnostic Products came in at $8,273M (vs $7,678M, +7.7%). Established Pharmaceutical Products Key Emerging Markets grew 8.0% to $4,167M. Total segment revenue was $44.3B.

The concentration of growth in Medical Devices — driven by the FreeStyle Libre CGM franchise and the structural heart portfolio — is the most important narrative in the 10-K.

Profitability: Stable and Well-Distributed

Per the consolidated statements of operations:

The 2024 net income of $13.4B is not comparable to other years — it included a large one-time gain (the 10-K footnotes typically disclose divestiture or investment accounting effects). EBITDA is a more reliable trend indicator, growing from $10.5B to $12.1B over two years.

Gross margin expansion of 100 basis points to 56.4% passes the B4 check. R&D and SG&A growth are both below revenue growth. Interest expense declined as debt was reduced.

Cash Flow: Clean and Growing

Per the consolidated statements of cash flows:

CFFO of $9.57B in 2025 exceeds net income of $6.52B — a ratio of 1.47x that confirms earnings are cash-backed. Free cash flow of $7.4B comfortably exceeds the dividend of $4.1B, leaving over $3B for share repurchases and debt paydown. The C1, C2, and C3 checks all pass. Accruals ratio is -3.5% (very low).

Abbott's cash conversion has improved substantially over three years: CFFO grew from $7.26B to $9.57B (+32%) while revenue only grew 10.5%.

The Accounts Receivable Issue

This is the first red flag on the screen. Per the balance sheet:

Our A2 check fails: AR outpaced revenue for two consecutive years, with the 2025 disparity being the widest (14.5% AR growth vs 5.7% revenue growth). DSO climbed by 5 days to 65 days. For a diversified healthcare company with Emerging Markets exposure (Established Pharmaceutical Products operates primarily in emerging markets), this is consistent with geographic mix shift but still warrants monitoring.

A1 passes because the 5-day DSO increase is within normal bounds. A3 passes because CFFO growth (+11.8%) exceeded revenue growth (+5.7%) — the cash is still flowing in.

Goodwill and Intangibles

D1 fails because the 57% ratio exceeds the 50% threshold, but the trend is improving — from 84% to 57% over two years as equity has grown and intangibles have amortized. Abbott has not made a large acquisition recently ($0 in 2024, $105M in 2025), so goodwill is stable. E2 passes because the goodwill+intangibles change is -1% YoY.

This is a "within normal range for a healthcare acquirer" situation — flagged mechanically, but clearly not a concern given the direction of travel.

Balance Sheet: Strong

C4 is flagged WATCH because cash covers 64% of total debt — below 100% but very healthy. Debt has been paid down by $1.2B in 2025. Debt/EBITDA of 1.1x (D2) is exceptionally low.

The 18-Point Screening

Beneish M-Score components: DSRI 1.084 (slightly elevated, matches A2 flag), GMI 0.982 (margin improved), AQI 0.975, SGI 1.057 (moderate growth), DEPI 1.111 (slightly elevated), SGAI 0.998, TATA -0.0351 (low), LVGI 0.925 (leverage declining).

Every component is in a normal range. The DSRI of 1.084 corresponds to the rising receivables — the two signals are consistent.

Altman Z-Score 4.90 is very strong. Components: X1 working capital/assets 0.09, X2 retained earnings/assets 0.40, X3 EBIT/assets 0.13, X4 equity/liabilities 1.51. No distress signals.

Key Risks from the 10-K (Item 1A)

The 10-K risk factors section addresses pharmaceutical/medical device company risks typical of a diversified operator:

1. Global Operations and Tax Uncertainty

Per the Critical Audit Matter disclosure: "unrecognized tax benefits were approximately $4.0 billion at December 31, 2025. The Company operates in a complex global tax environment and is subject to tax laws and regulations in numerous countries. Uncertain tax positions may arise from interpretations and judgments made by the Company in the application of the relevant tax statutes, regulations, rulings and case law across the numerous countries."

$4.0B is a very large unrecognized tax benefit — it represents tax positions Abbott has taken that it believes may not ultimately be sustained. Resolution could result in material cash outflows.

2. Emerging Markets Concentration in Established Pharmaceutical Products

The 10-K describes Established Pharmaceutical Products as "marketed and sold outside the United States in emerging markets" with customers ranging from "wholesalers, distributors, government agencies, healthcare facilities, pharmacies, and independent retailers." Revenue in Key Emerging Markets grew 8.0% reported and 9.5% on constant-currency. Currency volatility, foreign government price controls, and credit collection risk are structural.

3. Infant Formula Regulatory Oversight

Nutritional Products is Abbott's historically most-scrutinized segment since the Sturgis, Michigan infant formula plant shutdown in 2022 that caused national shortages. The segment now operates under intense FDA oversight. The 10-K does not disclose any new disruptions, but the regulatory framework remains stringent.

4. Medical Device Innovation and Competition

The Medical Devices segment, which grew 12.7% to $21.4B in 2025, includes the FreeStyle Libre CGM business that competes directly with DexCom's G7 and Medtronic's InPen/780G. The structural heart portfolio (MitraClip, TriClip) faces competition from Edwards Lifesciences (PASCAL) and others. Share losses in these high-margin segments would materially impact Abbott's growth story.

5. Pricing Pressure

Healthcare pricing pressure applies across all four segments — from Medicaid rebates on Ensure and Similac to insurer negotiation over MitraClip procedures to government tenders for Established Pharmaceutical Products. The 10-K discusses this in general terms throughout Item 1A.

Auditor's Critical Audit Matter: $4.0B in Unrecognized Tax Benefits

Ernst & Young LLP has served as Abbott's auditor since 2013. The 2025 audit identified one Critical Audit Matter: Income taxes — Unrecognized tax benefits.

Per the audit report: "unrecognized tax benefits were approximately $4.0 billion at December 31, 2025... Auditing the accounting for uncertain tax positions was challenging because the recognition of some of the uncertain tax positions in certain countries is judgmental and is based on interpretations of tax statutes, regulations, rulings and case law."

EY performed procedures that "included, among others, evaluating the technical merits of some of the Company's tax positions in certain countries, including the reasonableness of management's judgment with respect to the interpretation of tax laws and regulations." This is standard for a large multinational, but the $4.0B figure is substantial — it equals approximately 62% of full-year 2025 net income. A material adverse ruling could cause an earnings restatement.

Key Financial Trends (4-Year)

*2024 net income included a one-time gain; not comparable to operating earnings.

Summary

Grade: C. Two mechanical red flags on a strong underlying business.

Abbott's screening results are among the cleanest in large cap healthcare. CFFO of $9.57B covers net income of $6.52B by 1.47x. Free cash flow of $7.4B funds the $4.1B dividend and debt paydown with $3B+ to spare. Total debt has declined from $17.7B to $13.9B over three years while equity has grown from $36.7B to $52.1B. The Altman Z-Score of 4.90 is among the highest in the group, and PricewaterhouseCoopers' EY peers would happily trade.

The two failures on the screen are specific and explainable:

The auditor's Critical Audit Matter — $4.0B in unrecognized tax benefits — is the single item in the 10-K that warrants careful footnote reading. It is 62% of Abbott's 2025 net income and represents tax positions that "require significant auditor judgment" across numerous jurisdictions.

Read the 10-K. Read the segment footnotes on receivables by geography. Read Note 15 on uncertain tax positions. Then decide.

**Disclaimer**: This report is based on Abbott Laboratories' fiscal year 2025 10-K filed with the SEC on February 20, 2026. This is NOT investment advice.

**About EarningsGrade**: We screen earnings reports for financial red flags using an 18-point forensic framework. Grade C means a limited number of specific items warrant investigation.